Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.86 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TPH1 | P17752 | 1/20 | 0.53 |
| ▸ | GRB2 | P62993 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL2764615 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1857843 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL27035831 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL3039720 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL21250225 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL531185 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8896891 | 0.95 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1067115 | 0.95 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL9729320 | 0.95 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL25308979 | 0.94 | SLC7A5 (0.75) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445425-B2 | Urocortin-III and uses thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2013-05-21 | — | — | US | claimed |
| US-20120270792-A1 | UROCORTIN-III AND USES THEREOF | VALE JR WYLIE W (US) | 2012-10-25 | — | — | US | claimed |
| US-8084413-B2 | Urocortin-III and uses thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2011-12-27 | — | — | US | claimed |
| US-20090156493-A1 | UROCORTIN-III AND USES THEREOF | VALE JR WYLIE W | 2009-06-18 | — | — | US | claimed |
| EP-1368051-A4 | UROCORTIN-III AND USES THEREOF | RES DEV FOUNDATION (US) | 2005-11-02 | — | — | EP | claimed |
| US-6812210-B2 | REGULATION OF NEUROENDOCRINE AND PARACRINE RESPONSES TO STRESS. | RESEARCH DEVELOPMENT FOUNDATION | 2004-11-02 | — | — | US | claimed |
| US-20040143095-A1 | for treating high body temperature, appetite dysfunction, congestive heart failure, vascular disease, stress and anxiety; angiogenesis inhibitors; genetic engineering | RESEARCH DEVELOPMENT FOUNDATION | 2004-07-22 | — | — | US | claimed |
| EP-1368051-A2 | UROCORTIN-III AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2003-12-10 | — | — | EP | claimed |
| US-20030036507-A1 | Regulation of neuroendocrine and paracrine responses to stress. | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-20 | — | — | US | claimed |
| WO-2002074326-A2 | UROCORTIN-III AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2002-09-26 | — | — | WO | claimed |
| US-20160375102-A1 | UROCORTIN-III AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2016-12-29 | — | — | US | disclosed |
| US-9388229-B2 | Urocortin-III and uses thereof | RESEARCH DEVELOPMENT FOUNDATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140288161-A1 | UROCORTIN-III AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2014-09-25 | — | — | US | disclosed |
| US-8669092-B2 | Urocortin-III and uses thereof | Rsearch Development Foundation (US) | 2014-03-11 | — | — | US | disclosed |
| US-20140004603-A1 | UROCORTIN-III AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2014-01-02 | — | — | US | disclosed |
| US-6812210-B2 | REGULATION OF NEUROENDOCRINE AND PARACRINE RESPONSES TO STRESS. | RESEARCH DEVELOPMENT FOUNDATION | 2004-11-02 | — | — | US | disclosed |
| US-20040143095-A1 | for treating high body temperature, appetite dysfunction, congestive heart failure, vascular disease, stress and anxiety; angiogenesis inhibitors; genetic engineering | RESEARCH DEVELOPMENT FOUNDATION | 2004-07-22 | — | — | US | disclosed |
| EP-1368051-A2 | UROCORTIN-III AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030036507-A1 | Regulation of neuroendocrine and paracrine responses to stress. | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-20 | — | — | US | disclosed |
| WO-2002074326-A2 | UROCORTIN-III AND USES THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2002-09-26 | — | — | WO | disclosed |